Literature DB >> 21985940

Marginal recurrence requiring salvage radiotherapy after stereotactic body radiotherapy for spinal metastases.

Shlomo A Koyfman1, Toufik Djemil, Michael J Burdick, Neil Woody, Ehsan H Balagamwala, Chandana A Reddy, Lilyana Angelov, John H Suh, Samuel T Chao.   

Abstract

INTRODUCTION: We sought to quantify and identify risk factors associated with margin recurrence (MR) requiring salvage radiotherapy after stereotactic body radiation therapy (SBRT) for spinal metastases.
METHODS: We retrospectively reviewed patients with spinal metastases who were treated with single-fraction SBRT between 2006 and 2009. Gross tumor was contoured, along with either the entire associated vertebral body(ies) or the posterior elements, and included in the planning target volume. No additional margins were used. MR was defined as recurrent tumor within one vertebral level above or below the treated lesion that required salvage radiotherapy. Only patients who presented for 3-month post-SBRT follow-up were included in the analysis. Fine and Gray competing risk regression models were generated to identify variables associated with higher risks of MR. MR was plotted using cumulative incidence analysis.
RESULTS: SBRT was delivered to 208 lesions in 149 patients. Median follow-up was 8.6 months, and median survival was 12.8 months. The median prescribed dose was 14 Gy (10-16 Gy). MR occurred in 26 (12.5%) treated lesions, at a median time of 7.7 months after SBRT. Patients with paraspinal disease at the time of SBRT (20.8% vs. 7.6% of patients; p = 0.02), and those treated with <16 Gy (16.3% vs. 6.3% of patients, p = 0.14) had higher rates of MR. Both variables were associated with significantly higher risk of MR on multivariate analysis.
CONCLUSION: SBRT for spinal metastases results in a low overall rate of MR. The presence of paraspinal disease at the time of SBRT and a dose of <16 Gy were associated with higher risks of MR.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21985940     DOI: 10.1016/j.ijrobp.2011.05.067

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  A comparison of stereotactic body radiation therapy for metastases to the sacral spine and treatment of the thoracolumbar spine.

Authors:  Roman O Kowalchuk; Michael R Waters; K Martin Richardson; Kelly Spencer; James M Larner; Jason P Sheehan; William H McAllister; Charles R Kersh
Journal:  J Radiosurg SBRT       Date:  2020

2.  Comparison of deliverable IMRT and VMAT for spine metastases using a simultaneous integrated boost.

Authors:  Y K Lee; J L Bedford; H A McNair; M A Hawkins
Journal:  Br J Radiol       Date:  2013-02       Impact factor: 3.039

Review 3.  Stereotactic body radiotherapy for spinal metastases: a review.

Authors:  Lanlan Guo; Lixin Ke; Ziyi Zeng; Chuanping Yuan; Ziwei Wu; Lei Chen; Lixia Lu
Journal:  Med Oncol       Date:  2022-05-23       Impact factor: 3.064

4.  Comparing Outcomes of Oligometastases Treated with Hypofractionated Image-Guided Radiotherapy (HIGRT) with a Simultaneous Integrated Boost (SIB) Technique versus Metastasis Alone: A Multi-Institutional Analysis.

Authors:  Rachel F Shenker; Jeremy G Price; Corbin D Jacobs; Manisha Palta; Brian G Czito; Yvonne M Mowery; John P Kirkpatrick; Matthew J Boyer; Taofik Oyekunle; Donna Niedzwiecki; Haijun Song; Joseph K Salama
Journal:  Cancers (Basel)       Date:  2022-05-13       Impact factor: 6.575

5.  Prognostic factors associated with pain palliation after spine stereotactic body radiation therapy.

Authors:  Varun Puvanesarajah; Sheng-Fu Larry Lo; Nafi Aygun; Jason A Liauw; Ignacio Jusué-Torres; Ioan A Lina; Uri Hadelsberg; Benjamin D Elder; Ali Bydon; Chetan Bettegowda; Daniel M Sciubba; Jean-Paul Wolinsky; Daniele Rigamonti; Lawrence R Kleinberg; Ziya L Gokaslan; Timothy F Witham; Kristin J Redmond; Michael Lim
Journal:  J Neurosurg Spine       Date:  2015-07-31

6.  Effectiveness and safety of percutaneous vertebroplasty in the treatment of spinal metastatic tumor.

Authors:  Yilin Liu; Yuqiang Wang; Liang Zhao; Ruipeng Song; Hongyu Tan; Limin Wang
Journal:  Pak J Med Sci       Date:  2017 May-Jun       Impact factor: 1.088

7.  Spine Stereotactic Body Radiotherapy: Indications, Outcomes, and Points of Caution.

Authors:  Chia-Lin Tseng; Wietse Eppinga; Raphaele Charest-Morin; Hany Soliman; Sten Myrehaug; Pejman Jabehdar Maralani; Mikki Campbell; Young K Lee; Charles Fisher; Michael G Fehlings; Eric L Chang; Simon S Lo; Arjun Sahgal
Journal:  Global Spine J       Date:  2017-04-06

8.  Personalized Automation of Treatment Planning for Linac-Based Stereotactic Body Radiotherapy of Spine Cancer.

Authors:  Savino Cilla; Francesco Cellini; Carmela Romano; Gabriella Macchia; Donato Pezzulla; Pietro Viola; Milly Buwenge; Luca Indovina; Vincenzo Valentini; Alessio G Morganti; Francesco Deodato
Journal:  Front Oncol       Date:  2022-02-02       Impact factor: 6.244

Review 9.  Skeletal metastasis: treatments, mouse models, and the Wnt signaling.

Authors:  Kenneth C Valkenburg; Matthew R Steensma; Bart O Williams; Zhendong Zhong
Journal:  Chin J Cancer       Date:  2013-01-18

Review 10.  Stereotactic radiosurgery for spinal metastases: a literature review.

Authors:  Andrei Fernandes Joaquim; Enrico Ghizoni; Helder Tedeschi; Eduardo Baldon Pereira; Leonardo Abdala Giacomini
Journal:  Einstein (Sao Paulo)       Date:  2013 Apr-Jun
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.